Bicara Therapeutics Inc (BCAX)

Dec 10, 2025

There is no doubt that Bicara Therapeutics Inc (BCAX) ticks all the boxes. - Setenews

Dec 10, 2025

Dec 08, 2025

Promising Efficacy and Investment Potential for Bicara Therapeutics’ FICERA in Combination with Keytruda - TipRanks

Dec 08, 2025

Dec 08, 2025

Bicara stock maintains Buy rating at Stifel after ESMO-Asia data - Investing.com

Dec 08, 2025

Dec 08, 2025

Bicara Therapeutics Reports Promising Phase 1b Data - TipRanks

Dec 08, 2025

Dec 08, 2025

Buy Rating for Bicara Therapeutics Inc. Driven by Promising Clinical Data and Strategic Valuation - TipRanks

Dec 08, 2025

Dec 08, 2025

Bicara Therapeutics Inc Announces Preliminary Phase 1b Data - TradingView

Dec 08, 2025

Dec 07, 2025

Promising Phase 1/1b Results and Future Prospects Boost Bicara Therapeutics’ Buy Rating - TipRanks

Dec 07, 2025

Dec 07, 2025

Bicara announces preliminary data from Phase 1b cohort of ficerafusp alfa - TipRanks

Dec 07, 2025

Dec 06, 2025

Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026 - GlobeNewswire

Dec 06, 2025

Dec 05, 2025

Bicara Therapeutics (BCAX): Reassessing Valuation After Breakthrough Therapy Designation and Strong Phase 1b Data - Yahoo Finance

Dec 05, 2025

Dec 05, 2025

Will Bicara Therapeutics Inc. stock sustain high P E ratios2025 Biggest Moves & Verified Entry Point Detection - Newser

Dec 05, 2025

Dec 03, 2025

Skandinaviska Enskilda Banken AB publ Acquires 61,201 Shares of Bicara Therapeutics Inc. $BCAX - MarketBeat

Dec 03, 2025

Dec 02, 2025

Bicara Therapeutics (BCAX) Stock Analysis Report | Financials & Insights - Benzinga

Dec 02, 2025

Dec 02, 2025

Does Bicara Therapeutics Inc (BCAX) offer a good opportunity for investors? - Setenews

Dec 02, 2025

Dec 02, 2025

Positive Outlook for Bicara Therapeutics: Promising Phase 1b Results and Safety Profile Support Buy Rating - TipRanks

Dec 02, 2025

Dec 01, 2025

Bicara’s ficerafusp alfa shows consistent response rates at lower dose By Investing.com - Investing.com Australia

Dec 01, 2025

Dec 01, 2025

Bicara Therapeutics (BCTX) Releases Promising Early Data from Ca - GuruFocus

Dec 01, 2025

Dec 01, 2025

Bicara’s ficerafusp alfa shows consistent response rates at lower dose - Investing.com

Dec 01, 2025

Dec 01, 2025

Bicara Therapeutics Announces Publication of an Abstract with Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab in 1L HPV-negative R/M HNSCC at ESMO Asia 2025 - GlobeNewswire

Dec 01, 2025

Nov 30, 2025

Buy Rating for Bicara Therapeutics Driven by Promising Efficacy and Safety of FICERA in ESMO Asia Abstract - TipRanks

Nov 30, 2025

Nov 29, 2025

Bicara Therapeutics (NASDAQ:BCAX) Shares Down 3.3%Time to Sell? - MarketBeat

Nov 29, 2025

Nov 28, 2025

Wells Fargo Initiates Coverage of Bicara Therapeutics (BCAX) with Underweight Recommendation - MSN

Nov 28, 2025

Nov 27, 2025

What Analyst Ratings Reveal About Venus Pipes and Tubes Limiteds Future ValueShort-Term Trading Alerts & Turn Bull Runs into Life-Changing Wealth - earlytimes.in

Nov 27, 2025

Nov 27, 2025

What’s Bicara Therapeutics Inc (BCAX)’s Price to Earnings Ratio? - fostersleader.com

Nov 27, 2025

Nov 26, 2025

[424B5] Bicara Therapeutics Inc. Prospectus Supplement (Debt Securities) - Stock Titan

Nov 26, 2025

Nov 26, 2025

Hyep Ivan, Bicara Therapeutics CFO, sells $341k in BCAX stock - Investing.com Nigeria

Nov 26, 2025

Nov 25, 2025

Hyep Ivan, Bicara Therapeutics CFO, sells $341k in BCAX stock By Investing.com - Investing.com South Africa

Nov 25, 2025

Nov 25, 2025

Bicara Therapeutics president Cohlhepp sells $225k in shares By Investing.com - Investing.com South Africa

Nov 25, 2025

Nov 25, 2025

[Form 4] Bicara Therapeutics Inc. Insider Trading Activity - Stock Titan

Nov 25, 2025

Nov 25, 2025

Bicara Therapeutics president Cohlhepp sells $225k in shares - Investing.com

Nov 25, 2025

Nov 25, 2025

Bicara Therapeutics Executives Engage in Stock Sales - TradingView

Nov 25, 2025

Nov 25, 2025

Pres Cohlhepp Sells 12,500 ($225.6K) Of Bicara Therapeutics Inc [BCAX] - TradingView

Nov 25, 2025

Nov 25, 2025

Officer Raben Sells 11,000 ($205.1K) Of Bicara Therapeutics Inc [BCAX] - TradingView

Nov 25, 2025

Nov 25, 2025

Bicara Therapeutics: Intriguing Opportunity Given Rival Merus' $8B Buyout (NASDAQ:BCAX) - Seeking Alpha

Nov 25, 2025

Nov 25, 2025

Ready to Jump After Recent Trade: Bicara Therapeutics Inc (BCAX) - Setenews

Nov 25, 2025

Nov 21, 2025

CFO Hyep Files To Sell 605 Of Bicara Therapeutics Inc [BCAX] - TradingView

Nov 21, 2025

Nov 21, 2025

How Bicara Therapeutics Inc. stock reacts to job market data2025 Price Targets & Safe Entry Momentum Stock Tips - newser.com

Nov 21, 2025

Nov 20, 2025

Is Bicara Therapeutics Inc. stock safe for conservative investors - newser.com

Nov 20, 2025

Nov 19, 2025

Why Bicara Therapeutics Inc. stock appeals to analysts2025 Breakouts & Breakdowns & Reliable Momentum Entry Alerts - newser.com

Nov 19, 2025

Nov 19, 2025

What risks investors should watch in Bicara Therapeutics Inc. stock2025 EndofYear Setup & Consistent Income Trade Recommendations - newser.com

Nov 19, 2025

Nov 19, 2025

Should I hold or sell Bicara Therapeutics Inc. stock in 2025Insider Buying & Reliable Momentum Entry Alerts - newser.com

Nov 19, 2025

Nov 19, 2025

What dividend safety score for Bicara Therapeutics Inc. stockWall Street Watch & Long-Term Capital Growth Strategies - newser.com

Nov 19, 2025

Nov 19, 2025

Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $29.67 Average Price Target from Analysts - Defense World

Nov 19, 2025